Personalized colon cancer care in 2010

Seminars in Oncology

Volumn 38, Issue 2, 2011, Pages 284-308

  Catenacci, Daniel V T ^a   Kozloff, Mark ^a   Kindler, Hedy L ^a   Polite, Blase ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; B RAF KINASE; BEVACIZUMAB; CAPECITABINE; CEDIRANIB; CELECOXIB; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIREGULIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; LEVAMISOLE; MISMATCH REPAIR PROTEIN PMS2; MITOGEN ACTIVATED PROTEIN KINASE; OXALIPLATIN; PANITUMUMAB; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; ZK 7787;

ALOPECIA; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER THERAPY; CHEMOTHERAPY INDUCED EMESIS; CHROMOSOMAL INSTABILITY; COLON CANCER; COLORECTAL CANCER; DIARRHEA; DRUG CLEARANCE; DRUG ERUPTION; DRUG PROTEIN BINDING; GENE MUTATION; HAND FOOT SYNDROME; HETEROZYGOSITY LOSS; HUMAN; HYPERBILIRUBINEMIA; MICROSATELLITE INSTABILITY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; ONCOGENE N RAS; OVERALL SURVIVAL; PATIENT CARE; PERIPHERAL NEUROPATHY; PLOIDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RECURRENT CANCER; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

CHROMOSOMAL INSTABILITY; COLONIC NEOPLASMS; HUMANS; INDIVIDUALIZED MEDICINE; LOSS OF HETEROZYGOSITY; MUTATION; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PLOIDIES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79952964146     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2011.01.001     Document Type: Article

References (166)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 Ca Cancer J Clin 60 2010 277 300
2. L.K. Temple The prognosis of colon cancer is dependent on accurate staging J Surg Oncol 102 2010 1 2
3. S.B. Edge, D.R. Byrd, C.C. Compton, AJCC cancer staging manual 7th ed. 2010 Springer Verlag Philadelphia, PA
4. A. Grothey Adjuvant chemotherapy in colon canceris it worth it? Eur J Cancer 46 2010 1768 1769
5. D. Sargent, A. Sobrero, and A. Grothey Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials J Clin Oncol 27 2009 872 877
6. R. Gray, J. Barnwell, C. McConkey, R.K. Hills, N.S. Williams Quasar Collaborative Group Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study Lancet 370 2007 2020 2029
7. C. Tournigand, T. Andre, and E. Achille FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 2004 229 237 (Pubitemid 41095086)
8. P.F. Engstrom Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy Pharmacotherapy 28 2008 18S 22S
9. S. Siena, A. Sartore-Bianchi, F. Di Nicolantonio, J. Balfour, and A. Bardelli Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer J Natl Cancer Inst 101 2009 1308 1324
10. R.L. Schilsky Personalizing cancer care: American Society of Clinical Oncology presidential address 2009 J Clin Oncol 27 2009 3725 3730
11. A. Venook Critical evaluation of current treatments in metastatic colorectal cancer Oncologist 10 2005 250 261 (Pubitemid 40559590)
12. B. O'neil, H. Kelly, M. Morse, and R. Goldberg Colorectal cancer: evidence-based chemotherapy strategies L.B. Saltz, Adjuvant chemotherapy for colon cancer 2007 Humana Press Totowa, NJ 23
13. J.J. Lokich, J.D. Ahlgren, J.J. Gullo, J.A. Philips, and J.G. Fryer A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study J Clin Oncol 7 1989 425 432 (Pubitemid 19098135)
14. R.J. Fraile, L.H. Baker, T.R. Buroker, J. Horwitz, and V.K. Vaitkevicius Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion Cancer Res 40 1980 2223 2228 (Pubitemid 10082229)
15. G. Milano, J.M. Ferrero, and E. Francois Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation Br J Cancer 91 2004 613 617 (Pubitemid 39141612)
16. S. Gill, C.L. Loprinzi, and D.J. Sargent Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22 2004 1797 1806 (Pubitemid 41095169)
17. D.G. Haller, P.J. Catalano, and J.S. Macdonald Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089 J Clin Oncol 23 2005 8671 8678 (Pubitemid 46211510)
18. E.A. Poplin, J.K. Benedetti, and N.C. Estes Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer J Clin Oncol 23 2005 1819 1825 (Pubitemid 46211360)
19. C.H. Kohne, J. Wils, and M. Lorenz Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952 J Clin Oncol 21 2003 3721 3728 (Pubitemid 46606225)
20. P. Thirion, S. Michiels, and J.P. Pignon Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis J Clin Oncol 22 2004 3766 3775
21. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer Meta-analysis Group In Cancer J Clin Oncol 16 1998 301 308
22. A. de Gramont, J.F. Bosset, and C. Milan Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study J Clin Oncol 15 1997 808 815 (Pubitemid 27074252)
23. P. Rougier, R. Bugat, and J.Y. Douillard Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy J Clin Oncol 15 1997 251 260 (Pubitemid 27020581)
24. D. Cunningham, S. Pyrhonen, and R.D. James Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer Lancet 352 1998 1413 1418 (Pubitemid 28510874)
25. P. Rougier, E. Van Cutsem, and E. Bajetta Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer Lancet 352 1998 1407 1412 (Pubitemid 28510873)
26. L.B. Saltz, J.V. Cox, and C. Blanke Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer Irinotecan Study Group N Engl J Med 343 2000 905 914
27. J.Y. Douillard, D. Cunningham, and A.D. Roth Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial Lancet 355 2000 1041 1047 (Pubitemid 30162806)
28. O. Rixe, W. Ortuzar, and M. Alvarez Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel Biochem Pharmacol 52 1996 1855 1865 (Pubitemid 26419675)
29. A. de Gramont, A. Figer, and M. Seymour Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2000 2938 2947 (Pubitemid 30644117)
30. M.L. Rothenberg, A.M. Oza, and R.H. Bigelow Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial J Clin Oncol 21 2003 2059 2069 (Pubitemid 46606353)
31. R.M. Goldberg, D.J. Sargent, and R.F. Morton A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 2004 23 30 (Pubitemid 41095110)
32. J. Souglakos, N. Androulakis, and K. Syrigos FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG) Br J Cancer 94 2006 798 805
33. A. Falcone, S. Ricci, and I. Brunetti Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest J Clin Oncol 25 2007 1670 1676 (Pubitemid 46797946)
34. F. Montagnani, A. Chiriatti, G. Turrisi, G. Francini, and G. Fiorentini A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity Colorectal Dis 2010, Jan 12 [Epub ahead of print] PMID: 20070327
35. G. Masi, F. Loupakis, and L. Pollina Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases Ann Surg 249 2009 420 425
36. M. Miwa, M. Ura, and M. Nishida Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue Eur J Cancer 34 1998 1274 1281 (Pubitemid 28342121)
37. J. Schuller, J. Cassidy, and E. Dumont Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients Cancer Chemother Pharmacol 45 2000 291 297 (Pubitemid 30151522)
38. E. Van Cutsem, C. Twelves, and J. Cassidy Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study J Clin Oncol 19 2001 4097 4106 (Pubitemid 33049527)
39. P.M. Hoff, R. Ansari, and G. Batist Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study J Clin Oncol 19 2001 2282 2292 (Pubitemid 32366981)
40. E. Diaz-Rubio, J. Tabernero, and A. Gomez-Espana Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial J Clin Oncol 25 2007 4224 4230 (Pubitemid 47548562)
41. R. Porschen, H.T. Arkenau, and S. Kubicka Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group J Clin Oncol 25 2007 4217 4223 (Pubitemid 47548561)
42. J. Cassidy, S. Clarke, and E. Diaz-Rubio Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer J Clin Oncol 26 2008 2006 2012
43. J. Sakamoto, Y. Ohashi, C. Hamada, M. Buyse, T. Burzykowski, and P. Piedbois Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials J Clin Oncol 22 2004 484 492 (Pubitemid 41079778)
44. C.H. Kohne, J. De Greve, and J.T. Hartmann Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer EORTC study 40015 Ann Oncol 19 2008 920 926 (Pubitemid 351627308)
45. C.S. Fuchs, J. Marshall, and E. Mitchell Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study J Clin Oncol 25 2007 4779 4786 (Pubitemid 350086481)
46. D.G. Haller, J. Cassidy, and S.J. Clarke Potential regional differences for the tolerability profiles of fluoropyrimidines J Clin Oncol 26 2008 2118 2123
47. H.J. Schmoll, T. Cartwright, and J. Tabernero Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients J Clin Oncol 25 2007 102 109 (Pubitemid 350003057)
48. M. Koopman, N.F. Antonini, and J. Douma Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial Lancet 370 2007 135 142 (Pubitemid 47042893)
49. M.T. Seymour, T.S. Maughan, and J.A. Ledermann Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial Lancet 370 2007 143 152 (Pubitemid 47042894)
50. C. Tournigand, A. Cervantes, and A. Figer OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancera GERCOR study J Clin Oncol 24 2006 394 400 (Pubitemid 46630458)
51. B. Chibaudel, F. Maindrault-Goebel, and G. Lledo Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 study J Clin Oncol 27 2009 5727 5733
52. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342 (Pubitemid 38702844)
53. L.B. Saltz, S. Clarke, and E. Diaz-Rubio Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2008 2013 2019
54. A. Grothey, M.M. Sugrue, and D.M. Purdie Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE) J Clin Oncol 26 2008 5326 5334
55. http://www.clinicaltrials.gov/ct/show/NCT00499369.
56. http://webres.uccrc.org/clinical-trials.
57. http://clinicaltrials.gov/ct2/show/NCT00418938.
58. L.B. Saltz, L.S. Rosen, and J.L. Marshall Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy J Clin Oncol 25 2007 4793 4799 (Pubitemid 350086483)
59. J. Baselga Why the epidermal growth factor receptor? The rationale for cancer therapy Oncologist 7 Suppl 4 2002 2 8 (Pubitemid 34977157)
60. A. Bardelli, and S. Siena Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer J Clin Oncol 28 2010 1254 1261
61. D. Cunningham, Y. Humblet, and S. Siena Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345 (Pubitemid 38944402)
62. D.J. Jonker, C.J. O'Callaghan, and C.S. Karapetis Cetuximab for the treatment of colorectal cancer N Engl J Med 357 2007 2040 2048 (Pubitemid 350106711)
63. E. Van Cutsem, M. Peeters, and S. Siena Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J Clin Oncol 25 2007 1658 1664 (Pubitemid 46797944)
64. A. Cercek, and L. Saltz Evolving treatment of advanced colorectal cancer Curr Oncol Rep 12 2010 153 159
65. E. Van Cutsem, C.H. Kohne, and E. Hitre Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
66. C. Bokemeyer, I. Bondarenko, and A. Makhson Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 2009 663 671
67. M.W. Saif, and M. Shah K-ras mutations in colorectal cancer: a practice changing discovery Clin Adv Hematol Oncol 7 2009 45 53 64
68. J. Tol, M. Koopman, and A. Cats Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer N Engl J Med 360 2009 563 572
69. R.G. Amado, M. Wolf, and M. Peeters Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 2008 1626 1634
70. W. De Roock, B. Claes, and D. Bernasconi Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol 11 2010 753 762
71. W. De Roock, D.J. Jonker, and F. Di Nicolantonio Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab JAMA 304 2010 1812 1820
72. L.B. Saltz, H.J. Lenz, and H.L. Kindler Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study J Clin Oncol 25 2007 4557 4561 (Pubitemid 350035312)
73. J.R. Hecht, E. Mitchell, and T. Chidiac A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer J Clin Oncol 27 2009 672 680
74. T. Andre, C. Boni, and L. Mounedji-Boudiaf Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer N Engl J Med 350 2004 2343 2351 (Pubitemid 38702845)
75. J.P. Kuebler, H.S. Wieand, and M.J. O'Connell Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07 J Clin Oncol 25 2007 2198 2204 (Pubitemid 46954643)
76. T. Andre, C. Boni, and M. Navarro Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial J Clin Oncol 27 2009 3109 3116
77. http://clinicaltrials.gov/ct2/show/NCT00958737.
78. L.B. Saltz, D. Niedzwiecki, and D. Hollis Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: Results of CALGB 89803 J Clin Oncol 25 2007 3456 3461 (Pubitemid 47310883)
79. M. Ychou, W. Hohenberger, and S. Thezenas A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer Ann Oncol 20 2009 1964 1970
80. E. Van Cutsem, R. Labianca, and G. Bodoky Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3 J Clin Oncol 27 2009 3117 3125
81. C. Twelves, A. Wong, and M.P. Nowacki Capecitabine as adjuvant treatment for stage III colon cancer N Engl J Med 352 2005 2696 2704 (Pubitemid 41007824)
82. C.J. Allegra, G. Yothers, and M.J. O'Connell Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer J Clin Oncol 27 2009 3385 3390
83. B. Rousseau, B. Chibaudel, and J.B. Bachet Stage II and stage III colon cancer: treatment advances and future directions Cancer J 16 2010 202 209
84. S. Tejpar, M. Bertagnolli, and F. Bosman Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery Oncologist 15 2010 390 404
85. E. Mamounas, S. Wieand, and N. Wolmark Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04) J Clin Oncol 17 1999 1349 1355 (Pubitemid 29220839)
86. W.M. Grady, and J.M. Carethers Genomic and epigenetic instability in colorectal cancer pathogenesis Gastroenterology 135 2008 1079 1099
87. M. Meyers, M.W. Wagner, A. Mazurek, C. Schmutte, R. Fishel, and D.A. Boothman DNA mismatch repair-dependent response to fluoropyrimidine-generated damage J Biol Chem 280 2005 5516 5526 (Pubitemid 40280029)
88. A. Umar, C.R. Boland, and J.P. Terdiman Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability J Natl Cancer Inst 96 2004 261 268 (Pubitemid 38256271)
89. F.T. Bosman, P. Yan, and S. Tejpar Tissue biomarker development in a multicentre trial context: a feasibility study on the PETACC3 stage II and III colon cancer adjuvant treatment trial Clin Cancer Res 15 2009 5528 5533
90. M.M. Bertagnolli, D. Niedzwiecki, and C.C. Compton Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B protocol 89803 J Clin Oncol 27 2009 1814 1821
91. D.J. Sargent, S. Marsoni, and G. Monges Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer J Clin Oncol 28 2010 3219 3226
92. http://www.cancer.gov/clinicaltrials/ECOG-E5202.
93. 18F]FDG PET/CT imaging of colorectal cancer: a pictorial review Postgrad Med J 86 2010 174 182
94. R.A. Herbertson, A.F. Scarsbrook, S.T. Lee, N. Tebbutt, and A.M. Scott Established, emerging and future roles of PET/CT in the management of colorectal cancer Clin Radiol 64 2009 225 237
95. M. Moore, and P. Gibbs Adjuvant chemotherapy use among older patients with stage III colon cancer JAMA 303 2010 2353
96. D.J. Sargent, R.M. Goldberg, and S.D. Jacobson A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients N Engl J Med 345 2001 1091 1097
97. http://www.oncotypedx.com/en/Colon/HealthcareProfessional/Overview.aspx. 2010.
98. http://www.cancer.gov/clinicaltrials/EORTC-10041.
99. http://www.ascopost.com/articles/july-2010/multiparameter-breast-cancer- gene-profiling-assays.
100. A.D. Roth, S. Tejpar, and M. Delorenzi Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial J Clin Oncol 28 2010 466 474
101. J. Souglakos, J. Philips, and R. Wang Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer Br J Cancer 101 2009 465 472
102. S.E. Baldus, K.L. Schaefer, R. Engers, D. Hartleb, N.H. Stoecklein, and H.E. Gabbert Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases Clin Cancer Res 16 2010 790 799
103. P. Laurent-Puig, A. Cayre, and G. Manceau Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer J Clin Oncol 27 2009 5924 5930
104. R. Lieberman Personalized medicine enters the US marketplace: KRAS, anti-EGFR monoclonal antibodies, and colon cancer Am J Ther 16 2009 477 479
105. M. Moroni, S. Veronese, S. Benvenuti, A. Sartore-Bianchi, and F. Di Nicolantonio Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study G Lancet Oncol 6 2005 279 286 (Pubitemid 40590264)
106. B. Jacobs, W. De Roock, and H. Piessevaux Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab J Clin Oncol 27 2009 5068 5074
107. M. Varella-Garcia, J. Diebold, and D.A. Eberhard EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer J Clin Pathol 62 2009 970 977
108. M. Moroni, A. Sartore-Bianchi, S. Veronese, and S. Siena EGFR FISH in colorectal cancer: what is the current reality? Lancet Oncol 9 2008 402 403 (Pubitemid 351597789)
109. A. Sartore-Bianchi, K. Bencardino, and F. Di Nicolantonio Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer Target Oncol 5 2010 19 28
110. E. Van Cutsem Progress with biological agents in metastatic colorectal cancer leads to many challenges J Clin Oncol 24 2006 3325 3327 (Pubitemid 46638883)
111. 89Zr- bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922 J Nucl Med 51 2010 761 767
112. S.X. Yang, S.M. Steinberg, D. Nguyen, T.D. Wu, Z. Modrusan, and S.M. Swain Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer Clin Cancer Res 14 2008 5893 5899
113. N. Lassau, M. Chebil, L. Chami, S. Bidault, E. Girard, and A. Roche Dynamic contrast-enhanced ultrasonography (DCE-US): a new tool for the early evaluation of antiangiogenic treatment Target Oncol 5 2010 53 58
114. T.M. Pitts, A.C. Tan, and G.N. Kulikowski Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development Clin Cancer Res 16 2010 3193 3204
115. D.L. Reidy, E. Vakiani, and M.G. Fakih Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer J Clin Oncol 28 2010 4240 4246
116. B. Stecca, and I.A.A. Ruiz Context-dependent regulation of the GLI code in cancer by HEDGEHOG and non-HEDGEHOG signals J Mol Cell Biol 2 2010 84 95
117. R. Bagai, W. Fan, and P.C. Ma ARQ-197, an oral small-molecule inhibitor of c-Met for the treatment of solid tumors IDrugs 13 2010 404 414
118. Y. Zhang, B. Li, Z.Z. Ji, and P.S. Zheng Notch1 regulates the growth of human colon cancers Cancer 116 2010 5207 5218
119. https://www.protonet.fccc.edu/cgi-bin/protocol/proto-detail.cgi? protocol-id=ECOG4203&hosp-id=24. https://www.protonet.fccc.edu/cgi-bin/ protocol/proto-detail.cgi?protocol-id=ECOG4203&hosp-id=24.
120. E. Cecchin, F. Innocenti, and M. D'Andrea Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan J Clin Oncol 27 2009 2457 2465
121. N.J. Nelson Circulating tumor cells: will they be clinically useful? J Natl Cancer Inst 102 2010 146 148
122. M.Y. Kim, T. Oskarsson, and S. Acharyya Tumor self-seeding by circulating cancer cells Cell 139 2009 1315 1326
123. W.J. Allard, J. Matera, and M.C. Miller Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases Clin Cancer Res 10 2004 6897 6904 (Pubitemid 39383039)
124. http://www.veridex.com/cellsearch/CellSearchHCP.aspx.
125. S. Nagrath, L.V. Sequist, and S. Maheswaran Isolation of rare circulating tumour cells in cancer patients by microchip technology Nature 450 2007 1235 1239
126. S.J. Cohen, C.J. Punt, and N. Iannotti Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer J Clin Oncol 26 2008 3213 3221
127. S.J. Cohen, C.J. Punt, and N. Iannotti Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer Ann Oncol 20 2009 1223 1229
128. M.J. Yang, H.H. Chiu, and H.M. Wang Enhancing detection of circulating tumor cells with activating KRAS oncogene in patients with colorectal cancer by weighted chemiluminescent membrane array method Ann Surg Oncol 17 2010 624 633
129. P. Papavasiliou, T. Fisher, J. Kuhn, J. Nemunaitis, and J. Lamont Circulating tumor cells in patients undergoing surgery for hepatic metastases from colorectal cancer Proc (Bayl Univ Med Cent) 23 2010 11 14
130. D.A. Smirnov, D.R. Zweitzig, and B.W. Foulk Global gene expression profiling of circulating tumor cells Cancer Res 65 2005 4993 4997 (Pubitemid 40827303)
131. T. Gangadhar, and R.L. Schilsky Molecular markers to individualize adjuvant therapy for colon cancer Nat Rev Clin Oncol 7 2010 318 325
132. T. Tanaka, T. Watanabe, and Y. Kazama Chromosome 18q deletion and Smad4 protein inactivation correlate with liver metastasis: a study matched for T- and N- classification Br J Cancer 95 2006 1562 1567 (Pubitemid 44863360)
133. M.S. Pino, and D.C. Chung The chromosomal instability pathway in colon cancer Gastroenterology 138 2010 2059 2072
134. D. Fumagalli, P.G. Gavin, and Y. Taniyama A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes BMC Cancer 10 2010 101
135. J.J. Smith, N.G. Deane, and F. Wu Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer Gastroenterology 138 2010 958 968
136. J.H. Rho, S. Qin, J.Y. Wang, and M.H. Roehrl Proteomic expression analysis of surgical human colorectal cancer tissues: up-regulation of PSB7, PRDX1, and SRP9 and hypoxic adaptation in cancer J Proteome Res 7 2008 2959 2972
137. K.K. Lagerstedt, J. Staaf, and G. Jonsson Tumor genome wide DNA alterations assessed by array CGH in patients with poor and excellent survival following operation for colorectal cancer Cancer Inform 3 2007 341 355
138. H. Ashktorab, A.A. Schaffer, M. Daremipouran, D.T. Smoot, E. Lee, and H. Brim Distinct genetic alterations in colorectal cancer PLoS One 5 2010 e8879
139. D. Yee How to train your biomarker Clin Cancer Res 16 2010 3091 3093
140. J.E. Dancey, K.K. Dobbin, and S. Groshen Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents Clin Cancer Res 16 2010 1745 1755
141. R. Simon Roadmap for developing and validating therapeutically relevant genomic classifiers J Clin Oncol 23 2005 7332 7341 (Pubitemid 46202346)
142. S.J. Mandrekar, and D.J. Sargent Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges J Clin Oncol 27 2009 4027 4034
143. J. Tabernero, E. Aranda, and A. Gomez Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single-agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC): The MACRO Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [TTD]) J Clin Oncol 28 2010 15s (suppl; abstr 3501)
144. Tournigand, G. Lledo, and J. Delord Modified (m)Folfox7/bevacizumab (B) or modified (m)Xelox/bevacizumab with or without erlotinib (E) in first-line metastatic colorectal cancer (MCRC): Results of the feasibility phase of the DREAM-OPTIMOX3 study (GERCOR) J Clin Oncol 25(18S 2007 187s (suppl; abstr 4097)
145. R. Labianca, I. Floriani, and E. Cortesi Alternating versus continuous "FOLFIRI" in advanced colorectal cancer (ACC): A randomized "GISCAD" trial J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part I 24 2006 18S
146. R. Adams, R.H. Wilson, and M.T. Seymour Intermittent versus continuous oxaliplatin-fluoropyrimidine (Ox-Fp) chemotherapy (CT) in first-line treatment of patients (pts) with advanced colorectal cancer (aCRC): Predictive factors (PF), quality of life (QL), and final efficacy results from the MRC COIN trial J Clin Oncol ASCO Annual Meeting Proceedings 2010 (abstr 3525)
147. C. Kohne, E. Bajetta, and E. Lin Final results of CONFIRM 2: A multinational, randomized, double-blind, phase III study in 2nd line patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo J Clin Oncol ASCO Annual Meeting Proceedings Part I 25 2007 18S (abstr 4033)
148. E. Van Cutsem, I. Lang, and G. Folprecht Cetuximab plus FOLFIRI: Final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome J Clin Oncol 28 2010 15s (suppl; abstr 3570)
149. Douillard, J. Cassidy, and J. Jassem Randomized, open-label, phase III study of panitumumab (pmab) with FOLFOX4 versus FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST) J Clin Oncol 28 2010 15s (suppl; abstr 3528)
150. T.S. Maughan, R. Adams, and C.G. Smith Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in first-line advanced colorectal cancer (aCRC): Mature results of the MRC COIN trial J Clin Oncol 28 2010 15s (suppl; abstr 3502)
151. E. Van Cutsem, I. Lang, and G. Folprecht Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): The influence of KRAS and BRAF biomarkers on outcome: Updated data from the CRYSTAL trial ASCO GI Congress 2010 (abstr 281)
152. S. Tejpar, M. Peeters, and Y. Humblet Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data) J Clin Oncol 26 2008 (suppl; abstr 4001)
153. W. De Roock, J. De Schutter, and G. De Hertogh KRAS mutations preclude tumor shrinkage of colorectal cancers treated with cetuximab J Clin Oncol 25 2007 18s (suppl; abstr 4132)
154. D.G. Haller, J. Cassidy, and J. Tabernero Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): Impact of age on disease-free survival (DFS) J Clin Oncol (Meeting Abstracts) 28 2010 3521
155. N. Wolmark, G. Yothers, and M.J. O'Connell A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08 J Clin Oncol 27 2009 18s (suppl; abstr LBA4)
156. De Gramont, E. Van Cutsem, and J. Tabernero AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer J Clin Oncol 29 2011 (suppl 4; abstr 362)
157. R.M. Goldberg, D.J. Sargent, and S.N. Thibodeau Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147 J Clin Oncol 28 2010 15s (suppl; abstr 3508)
158. S.R. Alberts, D.J. Sargent, and T.C. Smyrk Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147 J Clin Oncol 28 2010 18s (suppl; abstr CRA3507)
159. S. Tejpar, F. Bosman, and M. Delorenzi Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial) J Clin Oncol 27 2009 15s (suppl; abstr 4001)
160. A. Roth, D. Klingbiel, and P. Yan Molecular and clinical determinants of survival following relapse after curative treatment of stage II-III colon cancer (CC): Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial J Clin Oncol 28 2010 15s (suppl; abstr 3504)
161. D. Kerr, R. Gray, and P. Quirke A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study J Clin Oncol 27 2009 15s (suppl; abstr 4000)
162. R. Rosenberg, M. Maak, U. Nitsche, et al. Independent validation of a prognostic genomic profile (ColoPrint) for stage II colon cancer (CC) patients. J Clin Oncol. 28:15s (suppl; abstr 3513).
163. E. Van Cutsem, Y. Humblet, and H. Gelderblom Cetuximab dose-escalation study in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic and efficacy data of a randomized study ASCO GI Congress 2007 (abstr 237)
164. V.E. Van Cutsem, I. Lang, and G. Folprecht Cetuximab plus FOLFIRI: Final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome J Clin Oncol 28 2010 15s (suppl; abstr 3570)
165. S. Vukelja, D. Richards, and L.T. Campos Randomized phase II study of perifosine in combination with capecitabine versus capecitabine alone in patients with second- or third-line metastatic colon cancer J Clin Oncol 27 2009 15s (suppl; abstr 4081)
166. P.K. Kreeger, and D.A. Lauffenburger Cancer systems biology: a network modeling perspective Carcinogenesis 31 2010 2 8